On the other hand, BRAF mutations, which are seen in 10% to 15% of CRC cases [90], usually lead to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, conferring high clinical aggressiveness, resistance to anti-EGFR monoclonal antibody therapy, and poor survival [91]. This evidence concerns the gene BRAF and colorectal carcinoma.